NeuroPace today released eight-year prospective clinical study data from trials of its closed-loop brain-responsive neurostimulation system, touting a 73% median seizure reduction among patients.
Data from the trials was presented at the American Epilepsy Society’s annual meeting in Washington D.C. this week, the Mountain View, Calif.-based company said.
The data came from 256 adult patients across feasibility trials, pivotal trials and long-term treatment trials and represented 1,825 implant years and an average follow-up of 8.1 years, NeuroPace said.
Results indicated a 73% median rate of seizure reduction at the eighth year, NeuroPace said, with a 90% seizure reduction rate or better in 30% of patients in the most recent three months. Seizure-free periods lasting one year or more were also experienced in 18% of patients, the company reported.
“In addition to compelling therapeutic benefits, the RNS System is the only device that provides information about a patient’s brain activity over months and years. With over 1.5 million stored brain recordings, the unprecedented data from the RNS System is helping us advance science. It is fueling research on seizure biomarkers, seizure forecasting, effects on memory, and possible synergies between specific antiepileptic medication and neuromodulation. We are optimistic that the clinical insights gained from this large body of data will continue to help clinicians improve their patients’ outcomes,” NeuroPace chief medical officer Dr. Martha Morrell said in a prepared statement.
In October, NeuroPace said it raised a $74 million funding round, saying it plans to use the infusion to speed the commercialization of its implantable neurostimulation device for treating epilepsy.
